{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"title":"Events"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}],"title":"Censored"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"PFS for the comparison II vs I will be measured from the date of randomization disclosure to the date of first observation of PD, or death from any cause as an event. Subjects who have not progressed or who withdraw from the study will be censored at the time of the last complete disease assessment. All subjects who were lost to FU will also be censored at the time of last complete disease assessment","groups":[{"description":"Early Treatment","id":"OG000","title":"Arm I"},{"description":"Late treatment","id":"OG001","title":"Arm II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This analysis included only patients in whom CPd vs Pd randomization was disclosed.","reportingStatus":"POSTED","timeFrame":"57 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Participants"}